Chronic / fibrotic hypersensitivity pneumonitis — management
fibrotic HP · Respiratory
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Fibrotic hypersensitivity pneumonitis results from chronic inhaled antigen exposure (birds, moulds, agricultural dusts) causing immune-mediated interstitial fibrosis. Antigen avoidance is central; immunosuppression and antifibrotics are used for inflammatory and progressive fibrotic phenotypes respectively.
Red flags
- Rapidly progressive dyspnoea / acute exacerbation
- Resting hypoxaemia
- Weight loss suggesting alternative diagnosis
- Continued antigen exposure despite advice
Assessment
Differential diagnosis
- Idiopathic pulmonary fibrosis
- Connective-tissue-disease ILD
- Sarcoidosis
- Drug-induced ILD
- Non-specific interstitial pneumonia
- Chronic pulmonary infection
Investigations
- HRCT (mosaic attenuation, air trapping, centrilobular nodules, upper/mid fibrosis)
- Detailed exposure history and specific IgG precipitins to suspected antigens
- Spirometry/lung volumes with DLCO (restriction, low transfer)
- Bronchoalveolar lavage lymphocytosis
- Serial inspiratory/expiratory CT for air trapping
- MDT discussion +/- surgical/transbronchial lung cryobiopsy when diagnosis unclear
Management
- Take an exhaustive exposure history (birds, feather bedding, mould, hot tubs, farming, metalworking fluids)
- Characterise HRCT pattern and assess for fibrosis and air trapping
- Confirm with BAL lymphocytosis and antigen-specific IgG where possible
- Discuss at an ILD MDT to reach a confident diagnosis and phenotype
- Identify and permanently eliminate the causative antigen (remediation, remove birds, change environment)
- Treat predominantly inflammatory disease with corticosteroids +/- steroid-sparing immunosuppression
- Start antifibrotic therapy for a progressive fibrotic phenotype
- Provide supportive care: pulmonary rehab, oxygen assessment, vaccination, comorbidity management
- Monitor lung function and HRCT for progression despite avoidance
- Refer progressive disease for lung transplant assessment
Drugs & doses
Prednisolone 0.5 mg/kg/day PO then taper over weeks for inflammatory disease
Mycophenolate mofetil 1 g PO twice daily as steroid-sparing agent
Azathioprine 1-2 mg/kg PO once daily alternative
Nintedanib 150 mg PO twice daily for progressive pulmonary fibrosis
Disposition
ILD specialist clinic / MDT; occupational-environmental remediation support; transplant referral for progressive disease.
Complications & pitfalls
- Progressive pulmonary fibrosis and respiratory failure
- Pulmonary hypertension
- Acute exacerbation with high mortality
- Immunosuppression-related infection
Exam pearls
- A clear inciting antigen is identified in only ~50% — absence does not exclude HP
- Antigen avoidance improves survival and is the single most important intervention
- A UIP-like fibrotic pattern on HRCT carries an IPF-like prognosis
- Nintedanib slows decline in progressive fibrosing HP regardless of underlying cause
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.